In addition, sitagliptin, an inhibitor of DPP-4 was reported to increase circulating EPCs in type 2 diabetic patients with concomitant up-regulation of stromal-derived factor-1α as well [78]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.